Editorial – Afederal judge in New York this week invalidated controversial patents on two human genes. At issue were genetic sequences known as BRCA-1 and BRCA-2 that could be used to gauge a woman’s susceptibility to certain types of breast and ovarian cancer. The patents, held by Myriad Genetics, gave the company a virtual monopoly on tests based on those genes. U.S. District Judge Robert W. Sweet ruled that the sequences were products of nature and that Myriad’s work to isolate them did not transform them into new, patentable products. In short, Myriad had, at best, discovered something, not invented it.
The Constitution gives Congress the power to grant patents for the sake of scientific progress. There’s a balancing test inherent in that power. more> http://bwbx.io/vRBd
![]()




